Lilly keeps on Novo's tail by reporting weekly insulin hits primary endpoint in 2 pivotal trials

Eli Lilly finds itself in a familiar position: snapping at the heels of Novo Nordisk. The Indianapolis-based drugmaker kept itself in the slipstream of its regular foe Thursday with positive top-line data from a pair of phase 3 studies of its once-weekly insulin candidate.